

Keywords: metastatic breast cancer; soluble VE-cadherin; prognostic factor; survival

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival

Pauline Rochefort¹, Sylvie Chabaud², Jean-Yves Pierga³, Olivier Tredan¹, Etienne Brain⁴, François-Clément Bidard³, Camille Schiffler², Helena Polena^{5,6,7}, Abir Khalil-Mgharbel^{5,6,7}, Isabelle Vilgrain^{5,6,7} and Thomas Bachelot^{*1}

¹Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, Lyon F-69373, France; ²Direction de la Recherche Clinique et de l'Innovation, Centre Léon Bérard, Lyon F-69373, France; ³Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, Paris F-95005, France; ⁴Department of Medical Oncology, Institut Curie - Hopital René Hugueneau, 35 Rue Dailly, Saint Cloud F-92210, France; ⁵INSERM, UMR-S 1036, Grenoble F-38054, France; ⁶University Grenoble-Alpes, Grenoble F-38000, France and ⁷CEA, DRF, Biosciences and Biotechnology Institute of Grenoble (BIG), Laboratory of Biology of Cancer and Infection, Grenoble F-38054, France

Background: Patients with metastatic breast cancer (MBC) represent a heterogeneous group, with large differences in outcomes from individual patients. VE-cadherin, an endothelial-specific cadherin, was shown to promote tumour proliferation and angiogenesis. Soluble VE-cadherin has been recently associated to breast cancer progression. This study was designed to investigate the prognosis significance of soluble VE-cadherin in hormone-refractory MBC.

Methods: Between 2004 and 2007, 150 patients with a fully documented history of hormone-refractory MBC were included in the prospective SEMTOF study. Serum concentrations of VE-cadherin were measured at inclusion for 141 patients and 6 weeks after the beginning of chemotherapy, using a sandwich enzyme immunoassay.

Results: The presence of high levels of serum VE-cadherin was significantly correlated to a shorter progression-free (PFS) and overall survival (OS). In a multivariate analysis along with clinical and biologic prognostic parameters, high serum VE-cadherin level was an independent adverse prognostic variable for PFS (median PFS 9.7 (IC95: 8; 11.9) vs 5.8 (IC95: 4.1; 8) months $P=0.0008$) and OS (median OS 34 (IC95: 26.6; 47.1) vs 14.8 (IC95: 9.3; 21.4) months $P=0.0007$). Moreover, VE-cadherin decrease during chemotherapy was also associated with good prognosis.

Conclusions: Serum VE-cadherin levels correlate to poorer survival in patients with hormone-refractory MBC. As sVE-cadherin reflects tumour angiogenesis, this could have therapeutic implications for antiangiogenic treatment.

Vascular endothelial (VE)-cadherin, also known as cadherin 5, is an endothelial-specific cadherin localised at adherens intercellular junctions of vascular endothelial cells (Giannotta *et al*, 2013). VE-cadherin plays an important role in the control of vascular

integrity and permeability (Dejana and Orsenigo, 2013; Bravi *et al*, 2014). VE-cadherin promotes tumour progression by contributing to tumour angiogenesis (Wallez *et al*, 2006) by interaction with VE growth factor receptor (VEGFR)-2 but also by enhancing tumour

*Correspondence: Dr T Bachelot; E-mail: Thomas.bachelot@lyon.unicancer.fr

Received 22 June 2016; revised 18 November 2016; accepted 1 December 2016; published online 5 January 2017

© 2017 Cancer Research UK. All rights reserved 0007–0920/17

cell proliferation via the transforming growth factor- β signalling pathway (Labelle *et al*, 2008a). Unlike most endothelial markers, VE-cadherin is not found in blood cells or in haematopoietic precursors. Cytokine-induced phosphorylation of the VE-cadherin cytoplasmic domain was reported to trigger cleavage of its extracellular domain, releasing soluble form of the protein—soluble VE-cadherin (sVE-cadherin) (Vilgrain *et al*, 2013). As a consequence, sVE-cadherin may be related to neoangiogenesis and tumour burden. We have previously shown that the cleavage of VE-cadherin is dependent upon tyrosine kinase activation in response to cytokines challenge and more precisely Src kinase in response to VEGF (Wallez *et al*, 2007; Vilgrain *et al*, 2013).

Breast cancer is the most common cancer type among women and it is the leading cause of cancer mortality among women in Europe (Ferlay *et al*, 2013; Arnold *et al*, 2015). Metastatic breast cancer (MBC) is generally considered as an incurable malignancy. Although therapeutic development has improved prognostic, median survival is still limited at 24–30 months after the diagnosis of metastasis (Largillier *et al*, 2008). MBC is a heterogeneous disease: actual survival for individual patients varies widely, from just a few months to several years. Thus, stratification of patients into poor and good prognosis groups would lead to better personalised therapeutic approach (Ryberg *et al*, 2001; Chang *et al*, 2003; Dawood *et al*, 2010). Additional biological parameters are therefore required to more accurately predict outcome of MBC patients (Kos and Dabbs, 2016). Recent studies have shown increase levels of sVE-cadherin in MBC compared with localised breast cancer (Fry *et al*, 2013, 2016). The SEMTOF study was a prospective study specifically designed to identify biological prognostic factor in patients with hormone-refractory MBC. Here we focused on sVE-cadherin results and its identification as an independent prognosis factor.

PATIENTS AND METHODS

Patients. The SEMTOF study was a multicentre prospective cohort study whose aim was to collect biological samples for prognostic and predictive translational analysis in hormone-refractory MBC patients. All patients agreed and signed an informed consent before inclusion. This study was done following international and national regulation in vigour at that time and was approved by the institutional ethics committee on 16 March 2004. Inclusion criteria were: age ≥ 18 years old, histologically proved MBC. Patients had to be eligible at inclusion to a first-line metastatic chemotherapy. Chemotherapy regimen was not pre-defined and was under investigator choice. All patients with HER2 positive disease received Trastuzumab associated with chemotherapy. Previous radiotherapy and hormonotherapy were allowed, patients had to be naive from metastatic chemotherapy. Progression after hormone therapy was defined as relapse occurring on the first year of adjuvant hormonotherapy, or progression within first 6 months of first-line hormonotherapy for MBC. They were included between July 2004 and 2007.

After obtaining patient informed consent, serum and matched plasma samples were collected, aliquoted and stored at -80°C , then thawed shortly before use.

Age, Eastern Cooperative Group PS, initial tumour stage, histology, HER2/neu status, initial number of positive lymph nodes, number and sites of metastases, biological parameters at inclusion (lactate dehydrogenase, haemoglobin, neutrophils count (PNN), time since diagnosis of the initial breast cancer (disease-free interval), prior chemotherapy or endocrine treatment (including the adjuvant setting) and the nature of the metastatic treatment were collected.

Clinical, biological and radiological evaluations were performed at inclusion, then every 6 weeks.

Serum analysis. Serum samples were kept frozen at -80°C and then thawed shortly before determination of sVE-cadherin level by ELISA assay. The assay was a sandwich enzyme immunoassay using a monoclonal antibody and an enzyme-linked polyclonal antibody specific for sVE-cadherin, as previously described (Vilgrain *et al*, 2013). Individual serum concentrations of sVE-cadherin are reported in $\mu\text{g ml}^{-1}$.

Statistical analysis. Statistical analyses were carried out using the SAS package 9.4. Patients' characteristics were described using median ($_{\min}$ max) or frequency and percentage for quantitative and qualitative parameters, respectively. Overall survival was defined as the time from inclusion to death of any cause or last news for alive patients. Progression-free survival was defined as the time from inclusion to the date of first documentation of progression or the date of death or date of last follow-up. Survival data were assessed by the Kaplan–Meier method. In the absence of assumptions concerning a hypothetical cut-off, two subgroups of comparable size were used to split population depending on sVE-cadherin level. In order to maximise the power of the study, the median value of the distribution score has been used. A second threshold, ($0.72 \mu\text{g l}^{-1}$) using outcome-based cut-point optimisation method defined with X-tile software was used (Camp *et al*, 2004). Survival curves were established according to the initial VE-cadherin level and compared using a Log-rank test. A step by step descending selection of variables was used so as to retain factors that were independently linked to survival parameters. The variables introduced in the multivariate Cox regression model were prognostic parameters previously described as being relevant in MBC, as biological subtype or parameters previously identify as significantly related to survival in the univariate procedure (Yamamoto *et al*, 1998; Largillier *et al*, 2008; Kwast *et al*, 2014). Significant variable (at 10% level) in the univariate approach were introduced in the initial multivariate model. The final multivariate model was those reduced to the only variables which were statistically significant at a 5% threshold.

RESULTS

Patients' characteristics. One hundred and fifty patients were included between July 2004 and 2007. Patients' characteristics are shown in Table 1. Median age was 56.6 years (range 30–84). Thirty patients (20%) presented metastasis at initial diagnosis. Eighty-seven patients had received adjuvant chemotherapy (AC, FEC, FAC and CMF). The median disease-free interval (from first diagnosis to recurrence) was 36.9 months varying from 0 to 289 months. All patients in this series had metastatic disease refractory to hormone therapy, that is, receptor-negative for both oestrogen and progesterone or progressive after hormone therapy. Twenty-six patients were HER2 positive, 18 patients (12.3%) had triple negative disease. Most patients had ductal ($n = 121$) rather than lobular ($n = 12$) histological subtype. Median soluble VE-cadherin value was not significantly different between this two groups.

Serum levels of sVE-cadherin. Initial sVE-cadherin serum level was assessed on 141 patients, with a median of $0.545 \mu\text{g ml}^{-1}$ (range 0.01 – $2.62 \mu\text{g ml}^{-1}$). A sVE-cadherin serum level at week 6 was assessed on 111 patients, with a median of $0.494 \mu\text{g ml}^{-1}$ (range 0.01 – $1.66 \mu\text{g ml}^{-1}$). A reduction of more than 10% of sVE-cadherin level at week 6 was observed in 40 patients.

Correlation of sVE-cadherin to clinico-pathological characteristics. We analysed sVE-cadherin correlation to accepted prognostic factors. Higher levels of sVE-cadherin were significantly correlated to a worse PS ($P = 0.048$), a lower haemoglobin

Table 1. Patients characteristics (N = 141)		
	No. of patients	Percent
Age (years)		
Median	56.6	
Range	(30–84)	
PS		
<2	119	84%
≥2	23	16%
Receptor status		
ER positive	102	72%
ER negative	39	27%
Her2/neu		
Positive	26	19%
Negative	115	81%
Liver metastasis		
Yes	54	36%
No	96	64%
Bone metastasis		
Yes	56	40%
No	85	60%
Number of metastatic sites		
≤4	124	88%
>4	17	12%
Lactate dehydrogenase		
≤600	109	78%
>600	31	22%

($P = 0.0492$) and a lower albumin ($P = 0.0391$). On the other hand, sVE-cadherin levels were not related to lactate dehydrogenase, PNN, disease-free interval and liver metastasis.

Prognostic value of sVE-cadherin for survival. At the time of analysis, with a median follow-up of 72.7 months, median survival of the entire patient population was 27.7 months from the date of sampling (IC95: 23.2–32.1). 125 patients (83.3%) deceased.

High serum level of sVE-cadherin was a factor of poor prognosis whatever the sVE-cadherin threshold used (median or Xtile cut-off). Median OS was, respectively, 33.4 (IC95: 26.1–49.8) vs 21.4 (IC95: 14.8–30.5) months (log-rank test: $P = 0.0063$) for patients whose serum level was below and above the median sVE-cadherin distribution value equals to $0.55 \mu\text{g ml}^{-1}$ (Figure 1). This significant prognosis effect is even more noticeable when a cut-off of 0.72 is used; median OS was, respectively, 34 (IC95: 26.6–47.1) vs 14.8 (IC95: 9.3–21.4) months (log-rank test: $P = 0.0007$) for patients whose serum level was below and above $0.72 \mu\text{g ml}^{-1}$ value (Figure 2). The death risk is twice higher in patients with sVE-cadherin level higher than $0.72 \mu\text{g ml}^{-1}$ HR = 2.0 (IC95: 1.3–3.0, $P = 0.0007$).

Significant difference in median PFS was also found between patients whose sVE-cadherin level was below or above $0.72 \mu\text{g ml}^{-1}$ value: 9.7 (IC95: 8–11.9) vs 5.8 (IC95: 4.1–8.0) months (log-rank test: $P = 0.0008$) (Figure 3).

Moreover, in univariate analysis, a decrease of 10% or more of sVE-cadherin between inclusion and week 6 was associated with improved OS: HR 1.65 (IC95: 1.06–2.57, log-rank test: $P = 0.025$) (Figure 4).

Multivariate analysis. A multivariate analysis of prognostic factors using the Cox model was performed on 119 out of 150 MBC patients without missing data. The variables introduced in the multivariate Cox regression included performance status (0–1 vs 2–3); bone involvement (present vs absent), adjuvant chemotherapy, disease-free interval, haemoglobin, SBR grade




Figure 1. Impact of VE-cadherin on OS, assessed by the Kaplan–Meier method, using $0.55 \mu\text{g ml}^{-1}$ cut-off.




Figure 2. Impact of VE-cadherin on OS, assessed by the Kaplan–Meier method, using $0.72 \mu\text{g ml}^{-1}$ cut-off.




Figure 3. Impact of VE-cadherin on PFS, assessed by the Kaplan–Meier method, using $0.72 \mu\text{g ml}^{-1}$ cut-off.

(I/II vs III) for OS only and sVE-cadherin level (≤ 0.72 vs $> 0.72 \text{ ng ml}^{-1}$). In the final model, sVE-cadherin remained an additional independent prognostic factor for OS: HR 1.672 (IC95: 1.1–2.64, $P = 0.0270$) (Table 2) and for PFS: HR 1.612 (IC95: 1.07–2.43, $P = 0.0219$).




Figure 4. VE-cadherin variation during chemotherapy impact on OS, assessed by the Kaplan-Meier method.

Table 2. Results of the multivariate analysis significant factors associated overall survival and hazard ratio

Factor	Median survival	P-value	HR	95% confidence interval of HR
Grade				
SBR1/2	39.0	0.0177	1.648	(1.09–2.5)
SBR3	21.2			
Haemoglobin (g dl⁻¹)				
< 11.5	28.4	0.0066	2.092	(1.22–3.56)
≥ 11.5	10.8			
Bone metastasis				
Yes	41.1	0.0009	2.096	(1.35–3.25)
No	19.0			
VE-cadherin (μg ml⁻¹)				
≤ 0.72	28.4	0.027	1.672	(1.1–2.64)
> 0.72	16.6			

DISCUSSION

Metastatic breast cancer is a heterogeneous disease with variable biological, clinical behaviours and for any specific patient, clinical evolution is difficult to predict. New prognostic and predictive factors are therefore needed to help clinicians choosing customised therapeutic strategy. Blood-based biomarkers have advantages over tissue markers as they are easily accessible and can also be routinely monitored.

Modification of VE-cadherin (or cadherin 5) expression has been observed in several cancer types, including breast cancer. In preclinical models, aberrant expression of VE-cadherin promotes tumour progression via the TGF- β pathway that leads to cell proliferation and to epithelial-mesenchymal transition, which is a phenotypic alteration associated with metastatic dissemination and progression (Labelle *et al*, 2008b; Fry *et al*, 2016).

VE-cadherin cytoplasmic domain contain several tyrosine residues that are targeted by tyrosine kinases upon cytokines challenge. We have previously shown that VEGF-induced VE-cadherin tyrosine phosphorylation at site Y685 upon Src kinase activation (Wallez *et al*, 2007). In addition, we have demonstrated that VEGF-induced VE-cadherin tyrosine phosphorylation preceded N-terminal ectodomain shedding of the protein (Vilgrain *et al*, 2013). The mechanism of VE-cadherin cleavage is not completely understood. One hypothesis is that the covalent tyrosine phosphorylation in

the cytoplasmic domain might induce a transconformation of the protein that could be more susceptible to proteolysis.

In this study, we have evaluated the clinical significance of soluble VE-cadherin levels in 141 hormone-refractory MBC patients. We demonstrate that sVE-cadherin is an independent prognostic factor in MBC for both PFS and OS. As sVE-cadherin had never been evaluated in this setting, we explored two thresholds based on statistical prediction. Elevated sVE-cadherin level (>0.72) was significantly associated with worse OS and PFS. Results of the multivariate analysis show that sVE-cadherin levels remain independent variables for survival when assessed with confirmed prognostic markers. Furthermore, a decrease of $\geq 10\%$ of sVE-cadherin level during chemotherapy was significantly associated with good prognosis.

Previous studies from Fry *et al* identified sVE-cadherin as a biomarker that distinguished patients with recurrent breast cancer from those with complete remission (Fry *et al*, 2013, 2016). These studies indicate that sVE-cadherin might be use as a biomarker to monitor patients after primary breast cancer treatment. This biomarker appears to be more sensitive than CA15.3. Those results indicate that measurements of sVE-cadherin could be integrated in the surveillance of patients with localised breast cancer, to early detect metastatic recurrence. Our study evaluated sVE-cadherin prognostic value on patients with established MBC. We demonstrated that sVE-cadherin value and evolution can discriminate patients with MBC into poor and good prognosis groups, which might help physicians to better personalised therapeutic approach. Due to different clinical situation and different ELISA technics, sVE-cadherin levels in our study cannot be directly compared with Fry *et al* values. Nevertheless, taken together those results highlight the informative value of sVE-cadherin in MBC.

In the absence of references concerning sVE-cadherin value in MBC, we chose in a first intention a cut-off based on median value. Cut-off of 0.72 was determined using X-tile software. It provides a global assessment of every possible way of dividing a population into low-high level marker expression. Additional analyses of sensitivity shown that the results did not vary when the cutoff changes. However, these cut-off can be discussed as they have no biological rational even if, they are twice associated with significantly statistical differences. Furthermore, we wanted to identify if variation of VE-cadherin level in the first weeks of treatment could be predictive of treatment response. We chose 10% cut-off in order to isolate patients with largest decreases in VE-cadherin at week 6 compared with baseline while having a sufficient sample size in this subgroup to keep enough statistical power to show a predictive effect of this evolution.

One other limit of our study is the heterogeneity of our cohort: we included patients with hormone receptor negative or positive disease and HER2 positive and negative disease. Because of our limited effective, we could not study either of the subtypes separately. Twenty-six patients had HER2-positive disease and they all received trastuzumab associated with metastatic first-line chemotherapy. However, soluble VE-cadherin median value was not statistically different in the different biological subtypes

Phase III trials in MBC reported PFS benefit of the adjunction of bevacizumab to taxanes but failed to demonstrate OS benefit (Miles *et al*, 2010; Brufsky *et al*, 2011; Robert *et al*, 2011). Part of the problem with bevacizumab development is the lack of predictive biomarker which could select for bevacizumab sensibility (Trédan *et al*, 2015). VEGF and VE-cadherin have been identified as mediator of tumour angiogenesis, a process required for invasion and metastasis of solid tumours (Weidner *et al*, 1991; Le Guelte *et al*, 2011). Although the role of VEGF in tumour progression has been largely demonstrated, studies failed to

identify soluble VEGF level as a predictive biomarker (Bachelot *et al*, 2003; Reeves *et al*, 2009). Vilgrain *et al* demonstrated in patients with glioblastoma that VEGF can induce VE-cadherin cleavage and consequently induce sVE-cadherin release. As it is a specific component of the endothelial cells and because it has not been reported to be trapped by extracellular matrix, soluble VE-cadherin in blood might reflect VEGF activity at tumour site (Vilgrain *et al*, 2013). Thus, sVE-cadherin might be a predictive biomarker of antiangiogenic treatment efficiency. This hypothesis is currently being tested in the prospective COMET study, which investigate various biological parameters that could be related to clinical benefit of bevacizumab in MBC.

In conclusion, we show that soluble VE-cadherin level is independently correlated with survival in hormone-refractory MBC. If confirmed, these results could help oncologists in identifying patients with a poor prognosis. Furthermore, as sVE-cadherin reflects active angiogenesis at tumour site, its evaluation might help to predict efficacy of antiangiogenic molecules.

ACKNOWLEDGEMENTS

This work was supported by the French National Institute of Health and Medical Research INSERM (UMRS 1036), the French Atomic Energy and Alternative Energies Commission (CEA), Department for Fundamental Research (DRF)/Institute of Biosciences and Biotechnologies of Grenoble: (BIG)/Invasion Mechanisms in Angiogenesis and Cancer (IMAC team)/Grenoble University Hospital, Institut National du Cancer (INCa) French Association against cancer (ARC Foundation), Fédération Nationale des Centres de Lutte contre le Cancer (GEFLUC Grenoble-Dauphiné -Savoie), Comité de la Loire et de la Saone et Loire de Ligue contre le Cancer. HP and AK-M were recipients of a grant from Association pour la Recherche contre le Cancer (ARC Foundation). We are indebted to Melanie Arboleas for technical assistance. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D, Soerjomataram I (2015) Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. *Eur J Cancer* **51**: 1164–1187.
- Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay J-Y (2003) Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. *Br J Cancer* **88**: 1721–1726.
- Bravi L, Dejana E, Lampugnani MG (2014) VE-cadherin at a glance. *Cell Tissue Res* **355**: 515–522.
- Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol* **29**: 4286–4293.
- Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. *Clin Cancer Res* **10**: 7252–7259.
- Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. *Cancer* **97**: 545–553.
- Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH (2010) Survival differences among women with de novo stage IV and relapsed breast cancer. *Ann Oncol* **21**: 2169–2174.
- Dejana E, Orsenigo F (2013) Endothelial adherens junctions at a glance. *J Cell Sci* **126**: 2545–2549.
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer* **49**: 1374–1403.
- Fry SA, Robertson CE, Swann R, Dwek MV (2016) Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion. *Br J Cancer* **114**: 1019–1026.
- Fry SA, Sinclair J, Timms JF, Leatham AJ, Dwek MV (2013) A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer. *Cancer Lett* **328**: 335–344.
- Giannotta M, Trani M, Dejana E (2013) VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. *Dev Cell* **26**: 441–454.
- Kos Z, Dabbs DJ (2016) Biomarker assessment and molecular testing for prognostication in breast cancer. *Histopathology* **68**: 70–85.
- Kwast ABG, Voogd AC, Menke-Pluijmers MBE, Linn SC, Sonke GS, Kiemeny LA, Siesling S (2014) Prognostic factors for survival in metastatic breast cancer by hormone receptor status. *Breast Cancer Res Treat* **145**: 503–511.
- Labelle M, Schnittler HJ, Aust DE, Friedrich K, Baretton G, Vestweber D, Breier G (2008a) Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. *Cancer Res* **68**: 1388–1397.
- Labelle M, Schnittler HJ, Aust DE, Friedrich K, Baretton G, Vestweber D, Breier G (2008b) Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor signaling. *Cancer Res* **68**: 1388–1397.
- Largillier R, Ferrero J-M, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, Balu-Maestro C, Marcy PY, Raouf I, Lallemand M, Chamorey E (2008) Prognostic factors in 1038 women with metastatic breast cancer. *Ann Oncol* **19**: 2012–2019.
- Le Guelte A, Dwyer J, Gavard J (2011) Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer. *Biol Cell* **103**: 593–605.
- Miles DW, Chan A, Dirix LY, Cortés J, Pivrot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol* **28**: 3239–3247.
- Reeves KW, Ness RB, Stone RA, Weissfeld JL, Vogel VG, Powers RW, Modugno F, Cauley JA (2009) Vascular endothelial growth factor and breast cancer risk. *Cancer Causes Control* **20**: 375–386.
- Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SYT, Zhou X, Phan S-C, O'Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. *J Clin Oncol* **29**: 1252–1260.
- Ryberg M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsky P (2001) Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. *Ann Oncol* **12**: 81–87.
- Trédan O, Lacroix-Triki M, Guiu S, Mouret-Reynier M-A, Barriere J, Bidard F-C, Braccini A-L, Mir O, Villanueva C, Barthélémy P (2015) Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. *Target Oncol* **10**: 189–198.
- Vilgrain I, Sidibé A, Polena H, Cand F, Mannic T, Arboleas M, Boccard S, Baudet A, Gulino-Debrac D, Bouillet L, Quesada J-L, Mendoza C, Lebas J-F, Pelletier L, Berger F (2013) Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker. *PLoS One* **8**: e80056.
- Wallez Y, Vilgrain I, Huber P (2006) Angiogenesis: the VE-cadherin switch. *Trends Cardiovasc Med* **16**: 55–59.

- Wallez Y, Cand F, Cruzalegui F, Wernstedt C, Souchelnytskyi S, Vilgrain I, Huber P (2007) Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. *Oncogene* **26**: 1067–1077.
- Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. *N Engl J Med* **324**: 1–8.
- Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, Takue Y, Narabayashi M, Adachi I, Takashima S (1998) Construction and

validation of a practical prognostic index for patients with metastatic breast cancer. *J Clin Oncol* **16**: 2401–2408.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.